Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease

Eur Respir J. 2020 Apr 23;55(4):1901240. doi: 10.1183/13993003.01240-2019. Print 2020 Apr.

Authors

Hadeel Khadawardi^{1

2

3}, Theodore K Marras^{1

2}, Mahtab Mehrabi², Sarah K Brode^{1

2

3}

Affiliations

¹ Dept of Medicine, University of Toronto, Toronto, ON, Canada.
² Joint Division of Respirology, Dept of Medicine, University Health Network and Sinai Health System, Toronto, ON, Canada.
³ West Park Healthcare Centre, Toronto, ON, Canada.

PMID: 31980493
DOI: 10.1183/13993003.01240-2019

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / adverse effects
Fluoroquinolones / adverse effects
Humans
Lung Diseases* / drug therapy
Mycobacterium avium Complex
Mycobacterium avium-intracellulare Infection* / drug therapy
Treatment Outcome

Substances

Anti-Bacterial Agents
Fluoroquinolones